Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urelumab in advanced solid malignancies
NCT00309023Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2005
- Primary completion
- Dec 2008
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of urelumab in melanoma, renal cell carcinoma (RCC) and ovarian carcinoma, sponsored by Bristol Myers Squibb. Primary endpoint: Assess Safety (Number and distribution and severity adverse events) at 2 years. Started Dec 2005; status: terminated.
02
Drugs
urelumab
03
Conditions
melanomarenal cell carcinoma (RCC)ovarian carcinoma
Beyond the preview
Go deeper on NCT00309023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309023.